Unicycive Therapeutics to Present at Annual Healthcare Conference

Got story updates? Submit your updates here. ›

Unicycive Therapeutics, a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced that CEO Shalabh Gupta, M.D. will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company's lead investigational treatment is oxylanthanum carbonate, a phosphate binding agent under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis. Unicycive's second treatment, UNI-494, is intended for acute kidney injury and has received orphan drug designation from the FDA.

Why it matters

As a clinical-stage biotech focused on kidney disease, Unicycive's participation in a major healthcare investment conference signals its progress in developing novel treatments for serious kidney conditions. Investor and analyst interest in the company's pipeline could help drive funding and awareness for its therapies targeting unmet medical needs.

The details

Unicycive Therapeutics will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:45 p.m. ET. The company's CEO, Shalabh Gupta, M.D., will provide an overview of Unicycive's lead investigational treatment, oxylanthanum carbonate, which is under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis. Unicycive's second therapy, UNI-494, is intended for acute kidney injury and has received orphan drug designation from the FDA for preventing delayed graft function in kidney transplant patients.

• Unicycive Therapeutics will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:45 p.m. ET.
• Unicycive's lead investigational treatment, oxylanthanum carbonate, is currently under review by the U.S. Food and Drug Administration (FDA).
• Unicycive's second investigational treatment, UNI-494, has completed a Phase 1 dose-ranging safety study in healthy volunteers and has received orphan drug designation from the FDA.

What’s next

Investors and analysts will be closely watching Unicycive's presentation at the Needham Healthcare Conference for updates on the company's pipeline, particularly the status of its lead therapy oxylanthanum carbonate under FDA review. The conference will provide a platform for Unicycive to showcase its progress and engage with the investment community.